Christoph Hasslacher

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Chantal Mathieu, Paresh Dandona, Pieter Gillard et al. · Diabetes Care · 2018 · 245 citations

Safety and Efficacy of Repaglinide in Type 2 Diabetic Patients With and Without Impaired Renal Function

Christoph Hasslacher · Diabetes Care · 2003 · 117 citations

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

Svenja Schumacher, I. Abbasi, Dale W. Weise et al. · European Journal of Clinical Pharmacology · 2001 · 94 citations

Chronic Kidney Disease, Pharmacology, Diabetes +9

Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study

Walter Zidek, Joachim Schrader, Stephan Lüders et al. · Cardiovascular Diabetology · 2012 · 94 citations · Full text